Glucosamine + Chondroitin + Msm

Verify with FDA CVM →

22 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
22
Total Reports
2
Deaths Reported
910.0%
Death Rate

Active Ingredients

Glucosamine + Chondroitin + Msm

Administration Routes

OralUnknown

Species Affected

Dog 21
Cat 1

Most Affected Breeds

Retriever - Labrador 7
Retriever - Golden 4
Pointing Dog - German Short-haired 2
Rottweiler 1
Boxer (German Boxer) 1
Collie (unspecified) 1
Dachshund (unspecified) 1
Pit Bull 1
Collie - Border 1
Terrier - Boston 1

Most Reported Reactions

Vomiting 8
Arthritis 5
Gastritis 3
Not eating 3
Lack of efficacy (endoparasite) - tapeworm 3
Lack of efficacy - NOS 2
Pain NOS 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Diarrhoea 2
Behavioural disorder NOS 2
Fluid in abdomen NOS 2
Elevated lactate 2

Outcome Breakdown

Outcome Unknown
10 (45.5%)
Ongoing
5 (22.7%)
Recovered/Normal
4 (18.2%)
Euthanized
1 (4.5%)
Recovered with Sequela
1 (4.5%)
Died
1 (4.5%)

Data Summary

Metric Value
Total adverse event reports 22
Reports involving death 2
Case-fatality rate (reported events) 910.0%
Distinct species in reports 2
Distinct breeds in reports 12
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Glucosamine + Chondroitin + Msm Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 22 adverse event reports referencing Glucosamine + Chondroitin + Msm, including 2 reports in which the animal died — a 910.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Glucosamine + Chondroitin + Msm. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Glucosamine + Chondroitin + Msm reports are Dog (21 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (7), Retriever - Golden (4), Pointing Dog - German Short-haired (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Glucosamine + Chondroitin + Msm are Vomiting (8), Arthritis (5), Gastritis (3), Not eating (3). Of the 22 reports with a coded outcome, Outcome Unknown is the leading category at 45.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Glucosamine + Chondroitin + Msm.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial